Sources and acquires pharmaceutical and healthcare products. In-licenses specialized healthcare products for commercialization. Now — the numbers.
This is an established company with proven profits.
Average growth of 11% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $20.0M would still be left in the vault — a solid cushion for hard times.
The market pays 19.9× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The net profit margin is 21% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 4 years, sales grew about 11% a year on average.
There is $20.6M in the vault; even if every debt were paid off, $20.0M would remain.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
The price action doesn’t yet back an upward turn. Council score: 3/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.